期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Anlotinib in combination with Envolizumab plus Etoposide for the treatment of EX-SCLC:a case report
1
作者 Hong-Lei Guo Hong Wang +3 位作者 Yan-Qi song xin-long song Ai-Di Wang Bao-Shan Liu 《Clinical Research Communications》 2024年第1期29-33,共5页
Background:Small cell lung cancer(SCLC)is an aggressive malignant tumor with strong immunosuppressive effects,characterized by rapid doubling time and poor prognosis.Currently,effective therapeutic options are urgentl... Background:Small cell lung cancer(SCLC)is an aggressive malignant tumor with strong immunosuppressive effects,characterized by rapid doubling time and poor prognosis.Currently,effective therapeutic options are urgently needed for Extensive-stage small-cell lung Cancer.Case description:In the present case,a combination therapy of anlotinib,envolizumab,and etoposide was administered to treat an 80-year-old female patient with extensive-stage SCLC accompanied by mediastinal lymph node and bone metastasis.After two cycles of treatment,the tumor lesions in the right lungs decreased from 5.04*3.44 cm to 1.65*1.42 cm.As of now,no significant mass is seen there and no serious adverse reactions in this patient.Until September 2023,she has survived for 18 months with no disease progression.Conclusions:Research shows that Alectinib,in combination with evolocumab plus etoposide,could be an original,viable therapeutic option for the treatment option of patients with extensive-stage SCLC. 展开更多
关键词 Extensive-stage Small Cell Lung Cancer ANTI-ANGIOGENESIS PD-1 inhibitors Combined treatment case report
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部